Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AgAIN: secukinumab versus ustekinumab in TNF inhibitor-experienced psoriatic arthritis
2019-004246-15Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Secukinumab arm with Ustekinumab arm (2 arms). Primary endpoint: Proportion of patients achieving a HAQ-DI response at Week 28. Started May 2020; status: completed.
02
Drugs
secukinumabustekinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2019-004246-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004246-15.